Empire Bluecross Prior Authorization Lookup
Latest Empire Bluecross prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2026-10-27Avlayah (tividenofusp alfa-eknm) Coverage for Neurologic Manifestations of MPS IIMedical-necessity and prior-authorization review for Avlayah under the member’s medical benefit, including initial and continuation therapy, quantity limits, coverage exclusions, and coding.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-27Rybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)This policy governs medical-necessity and prior-authorization coverage for amivantamab-vmjw and amivantamab/hyaluronidase-lpuj in adults with specified EGFR-mutated non-small cell lung cancer, including selected brain and leptomeningeal metastases. It applies to requests reviewed under the member's medical benefit.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-27Tevimbra (tislelizumab-jsgr) Coverage and Prior AuthorizationThis medical drug clinical policy governs prior authorization and medical necessity review for intravenous Tevimbra (tislelizumab-jsgr) in adults and other individuals with specified cancers. Coverage is available only for listed FDA-approved or NCCN-compendial indications when the stated disease, biomarker, treatment-line, combination-therapy, and prior-treatment criteria are met.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-18Levoleucovorin and Leucovorin AgentsThis policy governs medical-benefit coverage and clinical review, including prior authorization, for injectable levoleucovorin and leucovorin agents for methotrexate rescue or toxicity reduction, folic acid antagonist overdose, anemia, fluorouracil-based chemotherapy, and specified oncology indications.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-18Opdivo Qvantig (nivolumab hyaluronidase-nvhy) Coverage CriteriaThis policy governs medical-benefit clinical review and prior authorization for Opdivo Qvantig, including FDA-labeled and NCCN-supported oncology uses for specified cancers.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-18Saphnelo (anifrolumab-fnia) for systemic lupus erythematosusThis policy governs medical-benefit coverage and prior authorization for Saphnelo in adults with moderate-to-severe active systemic lupus erythematosus (SLE). It establishes initial and continuation criteria, non-approval conditions, approval durations, quantity limits, and applicable billing codes.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-18Sarclisa (isatuximab-irfc), Sarclisa Escena (isatuximab-irfc) Coverage CriteriaThis policy governs medical-benefit coverage and prior authorization for intravenous Sarclisa (isatuximab-irfc) and subcutaneous Sarclisa Escena in multiple myeloma. Coverage is based on age, diagnosis, prior therapy, transplant eligibility, disease status, and required combination regimens.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-18Vascular Endothelial Growth Factor (VEGF) InhibitorsGoverns medical-necessity review and applicable prior authorization for intravitreal VEGF antagonists used for retinal diseases, including age-related macular degeneration, diabetic retinal disease, retinal vein occlusion, and selected rare ocular conditions, when reviewed under the medical benefit.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-18Yartemlea (narsoplimab-wuug)This policy governs medical-necessity and prior-authorization review of Yartemlea (narsoplimab-wuug) for members with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Coverage is limited to individuals meeting the specified diagnosis, age, laboratory, renal, and exclusion-of-alternative-etiology criteria.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-01Denosumab AgentsThis policy governs medical-necessity, prior-authorization, step-therapy, quantity-limit, and coding requirements for Prolia, Xgeva, and listed denosumab biosimilars for osteoporosis, glucocorticoid-induced osteoporosis, treatment-induced bone loss, metabolic bone disease, malignancy-related indications, giant cell tumor of bone, and hypercalcemia of malignancy.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-01Trastuzumab AgentsThis policy governs medical-benefit coverage and clinical review, including prior authorization and step therapy, for Herceptin, Herceptin Hylecta, and specified trastuzumab biosimilars used for HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-28Decnupaz (pivekimab sunirine-pvzy) Coverage CriteriaThis policy governs medical-benefit coverage and prior authorization review for Decnupaz (pivekimab sunirine-pvzy). Coverage may be approved for individuals younger than 19 years or for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN); other indications are not approved.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-28Decnupaz (pivekimab sunirine-pvzy) Coverage for BPDCNThis policy governs prior authorization and medical-necessity review for Decnupaz (pivekimab sunirine-pvzy), with coverage available for individuals under 19 years of age or for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-28Hepcludex (bulevirtide-gmod) Coverage for Chronic Hepatitis Delta Virus InfectionThis policy governs prior authorization and medical necessity review for Hepcludex (bulevirtide-gmod) used to treat chronic hepatitis delta virus infection in adults. It applies to providers requesting initial or continuation coverage under the member's applicable benefit.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-28Saphnelo (anifrolumab-fnia) for systemic lupus erythematosusThis policy governs medical-necessity and prior-authorization review for Saphnelo (anifrolumab-fnia) used to treat adults with moderate to severe systemic lupus erythematosus as add-on therapy, including applicable coding and quantity limits.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-28Trutakna (atacicept-vymj) coverage for primary immunoglobulin A nephropathyThis policy governs prior authorization and medical-necessity review for Trutakna (atacicept-vymj) used to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. It applies to providers requesting coverage under a member's medical benefit or clinical review process.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-22Natalizumab Agents (Tysabri, Tyruko)Medical-necessity and prior-authorization coverage for Tysabri (natalizumab) and Tyruko (natalizumab-sztn) in adults with specified relapsing multiple sclerosis or moderately to severely active Crohn's disease, including Medicaid preferred-agent and step-therapy requirements.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-23Avlayah (tividenofusp alfa-eknm) Coverage CriteriaThis policy governs medical-necessity review and prior authorization for Avlayah in pediatric individuals with Mucopolysaccharidosis II (Hunter syndrome), including initial treatment, continuation therapy, quantity limits, and applicable billing codes. Coverage is limited to neurologic manifestations before advanced neurologic impairment.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-23Avlayah (tividenofusp alfa-eknm) Coverage CriteriaMedical-necessity and prior-authorization review for Avlayah in pediatric individuals with neurologic manifestations of Mucopolysaccharidosis II (Hunter syndrome), including initial and continuation therapy, quantity limits, and coding.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-23Lerochol (lerodalcibep-liga) Coverage CriteriaThis policy governs prior authorization and coverage of Lerochol, a monthly subcutaneous PCSK9 inhibitor used with diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It applies to providers requesting initial or continuation therapy and includes clinical criteria, step therapy, quantity limits, and billing codes.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-23Rybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Coverage CriteriaThis policy governs medical-benefit coverage and prior authorization for amivantamab-vmjw and amivantamab/hyaluronidase-lpuj in adults and individuals under 19 with specified recurrent, advanced, locally advanced, or metastatic non-small cell lung cancer. Coverage requires the applicable EGFR mutation, disease status, prior-treatment history, and combination or single-agent regimen described in the criteria.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-23Tevimbra (tislelizumab-jsgr) Coverage CriteriaThis policy governs medical-necessity and prior-authorization review for intravenous Tevimbra in adults and specified oncology indications. Coverage is subject to diagnosis, disease characteristics, prior therapy, biomarker results, treatment line, performance status, and combination regimen requirements.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-05-01Medicaid-Approved Preferred Drug List (PDL)A Medicaid Preferred Drug List governing coverage, prior authorization, quantity limits, specialty pharmacy and step therapy indicators for outpatient prescription drugs for members covered by Empire BlueCross Medicaid in North Carolina.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-04-22Levoleucovorin and Leucovorin AgentsMedical-benefit clinical review and prior authorization for injectable levoleucovorin and leucovorin agents, including Khapzory and Vykoura, for methotrexate rescue or toxicity reduction, selected oncology indications, anemia, and graft-versus-host disease prophylaxis.All Empire Bluecross updates
- Prior AuthClinical/Medical PolicyEff. 2026-04-22Loargys (pegzilarginase-nbln) Coverage CriteriaThis policy governs prior authorization and medical-necessity review for Loargys, an enzyme replacement therapy for adults and children 2 years of age or older with Arginase 1 Deficiency. Coverage requires diagnostic verification, concurrent dietary protein restriction, and additional response documentation for continuation therapy.All Empire Bluecross updates
Tool Description
Search Empire Bluecrossprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.